Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.
Employees: 1-10
Total raised: $35M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Panacea Ve... | panaceaven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.12.2018 | Series A | $35M | - |
Mentions in press and media 5
| Date | Title | Description |
| 04.12.2018 | Term Sheet — Tuesday, December 4 | THREE THINGS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop No more dinners with female colleagues. Don’t sit next to them on flights. Book hotel rooms on different floors. Avoid one-... |
| 03.12.2018 | Daily funding roundup - December 3rd, 2018 | Floom raised $2.5M: Ascent360 raised $4.1M; Chewse raised $19M; Oura raised $20M Floom: Floom is a tech-enabled marketplace for florists to sell their creations direct to customers. Floom has raised $2.5 million in seed funding led by First... |
| 03.12.2018 | Tactiva Therapeutics Secures $35 Million Series A Financing | Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series A financing and closed on the first tranche of the financing. Proceeds of... |
| 03.12.2018 | Tactiva Therapeutics Secures $35M in Series A Financing | Tactiva Therapeutics, a Buffalo, NY-based development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, secured a $35m Series A financing and closed on the first tranche of the financing. The round was led by ... |
| 03.12.2018 | Tactiva Therapeutics Secures $35M Series A | BUFFALO, NY, Tactiva Therapeutics has secured a $35 million Series A financing. >> Click here for more funding data on Tactiva Therapeutics >> To export Tactiva Therapeutics funding data to PDF and Excel, click here Tacti... |